Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia
Por:
Alberto Barcenas-Lopez, Diego, Karen Mendiola-Soto, Diana, Carlos Nunez-Enriquez, Juan, Manuel Mejia-Arangure, Juan, Hidalgo-Miranda, Alfredo, Jimenez-Morales, Silvia
Publicada:
1 ene 2021
Resumen:
Almost two decades ago, the sequencing of the human genome and high
throughput technologies came to revolutionize the clinical and
therapeutic approaches of patients with complex human diseases. In acute
lymphoblastic leukemia (ALL), the most frequent childhood malignancy,
these technologies have enabled to characterize the genomic landscape of
the disease and have significantly improved the survival rates of ALL
patients. Despite this, adverse reactions from treatment such as
toxicity, drug resistance and secondary tumors formation are still
serious consequences of chemotherapy, and the main obstacles to reduce
ALL-related mortality. It is well known that germline variants and
somatic mutations in genes involved in drug metabolism impact the
efficacy of drugs used in oncohematological diseases therapy. So far, a
broader spectrum of clinically actionable alterations that seems to be
crucial for the progression and treatment response have been identified.
Although these results are promising, it is necessary to put this
knowledge into the clinics to help physician make medical decisions and
generate an impact in patients' health. This review summarizes the gene
variants and clinically actionable mutations that modify the efficacy of
antileukemic drugs. Therefore, knowing their genetic status before
treatment is critical to reduce severe adverse effects, toxicities and
life-threatening consequences in ALL patients.
Filiaciones:
Alberto Barcenas-Lopez, Diego:
Inst Nacl Med Genom, Lab Genom Canc, Perifer Sur 4809, Mexico City 14610, DF, Mexico
Univ Nacl Autonoma Mexico, Programa Doctorado, Posgrad Ciencias Biol, Mexico City, DF, Mexico
Karen Mendiola-Soto, Diana:
Inst Nacl Med Genom, Lab Genom Canc, Perifer Sur 4809, Mexico City 14610, DF, Mexico
Univ Nacl Autonoma Mexico, Posgrad Ciencias Biol, Mexico City, DF, Mexico
Carlos Nunez-Enriquez, Juan:
Inst Mexicano Seguro Social, CMNSXXI, Unidad Invest Med Epidemiol Clin, Hosp Pediat, Mexico City, DF, Mexico
Manuel Mejia-Arangure, Juan:
Inst Mexicano Seguro Social, CMNSXXI, Unidad Invest Med Epidemiol Clin, Hosp Pediat, Mexico City, DF, Mexico
Inst Mexicano Seguro Social, Coordinac Invest Salud, Mexico City, DF, Mexico
Hidalgo-Miranda, Alfredo:
Inst Nacl Med Genom, Lab Genom Canc, Perifer Sur 4809, Mexico City 14610, DF, Mexico
Jimenez-Morales, Silvia:
Inst Nacl Med Genom, Lab Genom Canc, Perifer Sur 4809, Mexico City 14610, DF, Mexico
|